The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in miceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether the gut microbiome of patients with schizophrenia can alter brain chemistry and behavior. Researchers compared gut microbial communities of patients and healthy controls using 16S rRNA sequencing. They then transplanted patient or control stool into germ-free mice to see if schizophrenia-relevant behaviors transferred. Metagenomic and metabolomic analyses of the recipient mice probed the pathways by which the microbiome might influence the microbiota-gut-brain axis.
Who was studied?
The human cohort included 63 patients with schizophrenia and 69 healthy controls, matched for age, gender, and body mass index. Symptom severity was measured with the Positive and Negative Syndrome Scale. The animal arm used germ-free mice colonized with human stool. Groups received either schizophrenia microbiota or healthy-control microbiota. Recipient mice underwent behavioral tests plus whole-genome sequencing and metabolomics of stool, serum, and hippocampus.
What were the most important findings?
Patients with schizophrenia had lower microbial richness and diversity than controls. A panel of five families, Aerococcaceae, Bifidobacteriaceae, Brucellaceae, Pasteurellaceae, and Rikenellaceae, distinguished patients from controls with an area under the curve of 0.769. Mice receiving schizophrenia microbiota showed hyperactivity, reduced anxiety- and depressive-like behavior, and exaggerated startle responses versus mice given control microbiota. These mice had elevated glutamine in serum and hippocampus, decreased glutamate in stool and hippocampus, and increased hippocampal GABA, mirroring the glutamatergic disruption implicated in schizophrenia.
What are the greatest implications of this study?
The findings suggest the schizophrenia-associated microbiome can itself shift brain neurochemistry and produce schizophrenia-relevant behaviors, supporting a role for the microbiota-gut-brain axis in disease pathology. The microbial panel also hints at possible diagnostic value. Behavioral phenotypes in mice are nonspecific and shared across psychiatric conditions, so they do not prove the microbiome causes human schizophrenia. The work identifies mechanistic pathways worth further study rather than establishing causation.